Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseEarly Phase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismITFG1 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
An Open, Dose-escalation Clinical Study to Evaluation of the Safety and Efficiency of a Single Dose of CARC-101C in Patients With Autoimmune Type 1 Diabetes Mellitus
This study investigated the safety, efficiency, pharmacokinetics and pharmacokinetics of CARC-101C in patients with autoimmune type 1 diabetes. A single dose, dose escalation, open study design was used.
100 Clinical Results associated with Carcell Biopharma, Inc.
0 Patents (Medical) associated with Carcell Biopharma, Inc.
100 Deals associated with Carcell Biopharma, Inc.
100 Translational Medicine associated with Carcell Biopharma, Inc.